Individual Risk Factors of the Metabolic Syndrome in Adult Patients with Growth Hormone Deficiency – A Cross-sectional Case-control Study

Abstract

Objective: Growth hormone deficiency in adults (GHDA) is considered to be associated with increased cardiovascular risk, most commonly reflected by the prevalence of the metabolic syndrome (MS). However, there are still a limited number of studies comparing directly the MS prevalence in GHD patients to that in general population. The aim of this study was to investigate the individual risk factors of the MS in a cohort of GHD patients and to compare its prevalence with an age- and sex-matched control group.

Design: A cross-sectional case-control study.

Methods: In total, 54 adult patients with GHD (childhood onset GHD (COGHD): n=19, adult onset GHD (AOGHD): n=35) and 2 153 control subjects were studied. GHD was diagnosed according to the Endocrine Society Clinical Practice Guideline recommendations from 2011 and MS was scored by the NCEP-ATP III definition.

Results: The main metabolic abnormalities in GHD group were increased waist circumference (50.0%), low HDL-cholesterol (42.6%) and hypertriglyceridemia (40.7%) and their prevalence was significantly higher (p=0.013, p=0.019 and p=0.010, respectively) than in control group, where increased blood pressure prevailed (64.2%, p<0.0001). However, the difference in the MS prevalence between the 2 groups (29.6% vs. 24.9% in controls) failed to reach statistical significance (p=0.429). Patients with MS from both groups did not differ significantly in their metabolic profile (except for increased blood pressure), mean age and gender distribution.

Conclusions: Although GHDA was associated with the development of visceral obesity and dyslipidemia, these adverse cardiovascular risk factors did not determine a higher prevalence of the MS in Bulgarian GHD patients compared to control subjects. Furthermore, the individual risk factors of the MS did not significantly differ between patients with MS from both groups.

Key words

growth hormone deficiency - metabolic syndrome - abdominal obesity - dyslipidemia - cardiovascular risk

• References

• 1 Abs R, Feldt-Rasmussen U, Mattsson AF et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults – a KIMS database analysis. Eur J Endocrinol 2006; 155: 79-90
• 2 Verhelst J, Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults. Eur J Endocrinol 2009; 161: 41-49
• 3 Lim HH, Kang MJ, Yun IS et al. Prevalence and risk factors of the metabolic syndrome in young adults with childhood-onset hypopituitary growth hormone deficiency. Korean J Pediatr 2010; 53: 892-897
• 4 Gazzaruso C, Gola M, Karamouzis I et al. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH – an update. J Clin Endocrinol Metab 2014; 99: 18-29
• 5 Johansson JO, Fowelin J, Landin K et al. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995; 44: 1126-1129
• 6 Rosén T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288
• 7 Bates AS, Van’t Hoff W, Jones PJ et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81: 1169-1172
• 8 Bülow B, Hagmar L, Mikoczy Z et al. Increased cerebrovascular mortality in patients with hypopituitarism. J Clin Endocrinol Metab 1997; 46: 75-81
• 9 Svensson J, Bengtsson B-Å, Rosen T et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004; 89: 3306-3312
• 10 Tomlinson JW, Holden N, Hills RK et al. Association between premature mortality and hypopituitarism. West Midland Prospective Hypopituitarism Group. Lancet 2001; 357: 425-431
• 11 Bengtsson B-Å. Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism. Growth Horm IGF Res 1998; 8: 480-485
• 12 al-Shoumer KA, Gray R, Anyaoku V et al. Effects of four years’ treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf) 1998; 48: 795-802
• 13 Gibney J, Wallace JD, Spinks T et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84: 2596-2602
• 14 Gillberg P, Bramnert M, Thoren M et al. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Horm IGF Res 2001; 11: 273-281
• 15 Götherström G, Svensson J, Koranyi J et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001; 86: 4657-4665
• 16 Svensson J, Fowelin J, Landin K et al. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2121-2127
• 17 Claessen KM, Appelman-Dijkstra NM, Adoptie DM et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 2013; 98: 352-361
• 18 van der Klaauw A, Biermasz N, Feskens E et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 2007; 156: 455-462
• 19 Attanasio AF, Mo D, Erfurth EM et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 2010; 95: 74-81
• 20 Claessen KM, Appelman N, Pereira AM et al. Abnormal metabolic phenotype in middle-aged growth hormone deficient (GHD) adults despite long-term recombinant human GH (rhGH) replacement. Eur J Endocrinol 2013; 170: 265-274
• 21 Burger AG, Monson JP, Colao AM et al. Cardiovascular risk in patients with growth hormone deficiency: effects of growth hormone substitution. Endocr Pract 2006; 12: 682-689
• 22 van Bunderen CC, van Nieuwpoort IC, Arwert LI et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011; 96: 3151-3159
• 23 Molitch ME, Clemmons DR, Malozowski S et al. Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1587-1609
• 24 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) . Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
• 25 Salomon F, Cuneo RC, Hesp R et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803
• 26 Verhelst J, Mattsson AF, Luger A et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 2011; 165: 881-889
• 27 Murray RD, Wieringa G, Lawrance JA et al. Partial growth hormone deficiency is associated with an adverse cardiovascular risk profile and increased carotid intima-medial thickness. Clin Endocrinol (Oxf) 2010; 73: 508-515
• 28 Schneider HJ, Klotsche J, Wittchen HU et al. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 2011; 75: 825-830
• 29 Attanasio AF. Childhood onset adult growth hormone deficiency and hypopituitarism: a black box. In: Webb S, Chanson P. A decade of HypoCCS: the changing face of pituitary disease. Bristol, UK: Bioscentifica Ltd; 2008: 61-71
• 30 Attanasio AF, Lamberts SW, Matranga AM et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997; 82: 82-188